Intra-Cellular Therapies (ITCI) saw its loss narrow to $26.93 million, or $0.62 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $27.84 million, or $0.64 a share. Revenues for the quarter were $0.10 million. The company has not recorded any revenues for the previous year period.
Operating loss for the quarter was $27.75 million, compared with an operating loss of $28.50 million in the previous year period.
"We, at ITCI, are committed to developing innovative treatments that can provide broad efficacy without many of the safety and tolerability issues associated with current therapies thereby reducing the burden on patients and their caregivers," said Dr. Sharon Mates, chairman and chief executive officer of ITCI.
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
